Kester’s Evestia Clinical acquires ICRC-Weyer

Kester, a leading sector-focused private equity firm, is pleased to announce that Evestia Clinical (“Evestia”) has acquired ICRC-Weyer, a German headquartered clinical research organisation (“CRO”) and scientific consultancy.

This transaction represents Evestia’s second acquisition since Kester’s investment in December 2024, following the acquisition of Atlantic Research Group in July 2025. The combined group will continue to be led by the Evestia executive team, who will be joined by Johann Daniel Weyer (ICRC-Weyer MD).

Based in Berlin, ICRC-Weyer brings a strong heritage in data-driven research, with deep expertise in biostatistics, data management, and medical writing across the full clinical development cycle. Integrating these specialist capabilities will expand Evestia’s European presence and gives its clients enhanced access to high-quality services that are increasingly critical as clinical trial development grows in complexity and regulatory expectations evolve. At the same time, ICRC-Weyer’s clients will benefit from access to Evestia’s full suite of global clinical trial services from Phase I-III and beyond, providing more integrated, end-to-end support across core therapeutic areas including oncology, neurology, and rare diseases.

Richard Barfield, Chairman of Evestia Clinical, said: “As we mark one year since the launch of Evestia Clinical, this acquisition is another significant step in our strategy to build a truly global, independent specialist CRO with the capabilities to support biotech innovators worldwide. Our expanded specialist capabilities strengthen Evestia Clinical’s position as a trusted, full-service partner for biotech innovators advancing complex therapies in oncology, neurology, and rare diseases.”

Adam Maidment, Managing Partner of Kester, said: “The addition of ICRC is an exciting next step in Evestia’s goal to become a truly global specialist CRO that provides high-quality, tailored services to clients. We look forward to working with the ICRC team and continuing to support Evestia in its growth ambitions, both organically and through further acquisitions.”